Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -2.82 is 44% below its 5-year average of -1.96, near the low end of its 5-year range (-2.82–-1.22).
2.55% below its 12-month average of -2.75.
Reported quarterly EPS; no daily interpolation. Q1 FY2027 (2026-06-30): -0.75.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 24 comparable quarters.
EARNINGS PER SHARE (EPS)
-2.82
EARNINGS PER SHARE (EPS) AVG TTM
-2.75
EARNINGS PER SHARE (EPS) AVG 3Y
-2.27
EARNINGS PER SHARE (EPS) AVG 5Y
-1.96
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-2.55%
CURRENT VS 3Y AVG
-24.09%
CURRENT VS 5Y AVG
-44.12%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Immunovant, Inc.
Market Cap
$6.55B
Earnings Per Share (EPS)
-2.82
TTM Avg
-2.75
3Y Avg
-2.27
5Y Avg
-1.96
Market Cap
$6.57B
Earnings Per Share (EPS)
-0.63
TTM Avg
0.57
3Y Avg
0.18
5Y Avg
-0.06
Market Cap
$6.50B
Earnings Per Share (EPS)
4.14
TTM Avg
3.99
3Y Avg
3.29
5Y Avg
1.98
Market Cap
$6.49B
Earnings Per Share (EPS)
0.49
TTM Avg
-0.07
3Y Avg
-0.37
5Y Avg
-0.14
Market Cap
$6.66B
Earnings Per Share (EPS)
19.92
TTM Avg
19.26
3Y Avg
18.34
5Y Avg
18.42
Market Cap
$6.25B
Earnings Per Share (EPS)
-3.11
TTM Avg
-3.72
3Y Avg
-3.54
5Y Avg
-3.08
Market Cap
$6.02B
Earnings Per Share (EPS)
-9.75
TTM Avg
-37.33
3Y Avg
-73.93
5Y Avg
-56.40
Market Cap
$5.94B
Earnings Per Share (EPS)
9.35
TTM Avg
3.11
3Y Avg
1.82
5Y Avg
1.76
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunovant, Inc. (IMVT) | $6.55B | -2.82 | -2.75 | -2.27 | -1.96 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.57B | -0.63 | 0.57 | 0.18 | -0.06 |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.50B | 4.14 | 3.99 | 3.29 | 1.98 |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.49B | 0.49 | -0.07 | -0.37 | -0.14 |
| Chemed Corporation (CHE)vs › | $6.66B | 19.92 | 19.26 | 18.34 | 18.42 |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.25B | -3.11 | -3.72 | -3.54 | -3.08 |
| Alkermes plc (ALKS)vs › | $6.99B | 0.38 | 1.85 | 1.22 | 0.64 |
| GRAIL Inc. (GRAL)vs › | $6.02B | -9.75 | -37.33 | -73.93 | -56.40 |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.94B | 9.35 | 3.11 | 1.82 | 1.76 |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.91B | -0.70 | -1.19 | -1.69 | -1.81 |
Trailing EPS (TTM)
$-2.82
Forward EPS (Est.)
$-2.94
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2026-03-31 | -2.77 |
| 2025-03-31 | -2.73 |
| 2024-03-31 | -1.88 |
| 2023-03-31 | -1.71 |
| 2022-03-31 | -1.43 |
| 2021-03-31 | -1.22 |
| 2020-03-31 | -1.54 |
| 2019-03-31 | 0.00 |
| 2018-03-31 | -13.68 |
